Objective: TANK Binding Kinase 1 (TBK1) has been implicated in the regulation of metabolism through studies with the drug amlexanox, an inhibitor of the IkB kinase (IKK)-related kinases. Amlexanox induced weight loss, reduced fatty liver and insulin resistance in high fat diet (HFD) fed mice and has now progressed into clinical testing for the treatment and prevention of obesity and type 2 diabetes. However, since amlexanox is a dual IKKε/TBK1 inhibitor, the specific metabolic contribution of TBK1 is not clear. Methods: To distinguish metabolic functions unique to TBK1, we examined the metabolic profile of global Tbk1 mutant mice challenged with an obesogenic diet and investigated potential mechanisms for the improved metabolic phenotype. Results and conclusion: We report that systemic loss of TBK1 kinase function has an overall protective effect on metabolic readouts in mice on an obesogenic diet, which is mediated by loss of an inhibitory interaction between TBK1 and the insulin receptor.
INTRODUCTION
The prevalence of obesity has expanded dramatically over the last 30 years worldwide and has contributed to the increasing health burden of associated complications, including insulin resistance, type 2 diabetes, cardiovascular disease, hypertension, liver steatosis and dyslipidemia [1e3] . A primary pathology of obesity and metabolic disorders is the induction of chronic low-grade, unresolved inflammation in organs pertinent to energy homeostasis. This so-called "meta-inflammation" consists of increased levels of proinflammatory cytokines and macrophage infiltration in white adipose tissue (WAT) and is coincident with the manifestation of insulin resistance [4e6] . While the etiology of insulin resistance is complicated and multifaceted, numerous studies have demonstrated that blocking inflammatory mediators through genetic or pharmacological means results in improved insulin and glucose tolerance [7e12] . NF-kB is a major transcriptional driver of inflammation that is activated in response to cytokines and pathogenic stimuli to promote the upregulation of inflammatory and immune regulatory gene expression. Not surprisingly, NF-kB is chronically active in many inflammatory diseases and over the past two decades has gained significant attention in the metabolism field due to its high-level activity in affected tissues [13, 14] . Most metabolic studies have centered on canonical NF-kB activators, such as IKKa and IKKb; however, Chiang and colleagues [14] reported that the noncanonical activators, IKKε and TBK1, are more highly expressed than canonical activators in metabolically affected tissues of obese animals. Subsequent investigations revealed that Ikbke À/À mice and mice treated with amlexanox (a dual IKKε/ TBK1 small molecule inhibitor) are protected from diet-induced obesity (DIO) and associated metabolic syndrome conditions [14, 15] . This protection is thought to result from loss of TBK1 and IKKε metabolic functions in repressing adaptive energy expenditure in a diet-driven inflammatory state. Due to the embryonic lethality of Tbk1 À/À mice and the nature of amlexanox as a dual IKKε and TBK1 inhibitor, distinguishing metabolic functions unique to TBK1 remains a challenge [16] . As amlexanox enters the clinical space for the treatment of obesity and type 2 diabetes in human trials, it has become increasingly important to understand the implications of systemic TBK1 inhibition during metabolic stress. We set out to investigate TBK1-dependent contributions to metabolism in a metabolically challenged rodent model. We did this utilizing a Tbk1 mutant mouse that harbors two copies of a null Tbk1 allele (Tbk1 D/D ) [17] . This particular "null allele" encodes a truncated TBK1 protein that is catalytically inactive and expressed at low levels, thereby allowing analysis of global TBK1 kinase loss in vivo. Recently, Zhao and colleagues [18] reported the metabolic effects of an adipocyte specific Tbk1-deficient animal model. Here, we focus on the analysis of a global loss-of-function mutant, which provides an opportunity to evaluate the function of TBK1 in a wider context than just the adipocyte.
We report that Tbk1 D/D mice are resistant to high fat diet-induced weight gain and pancreatic islet hyperplasia and hypertrophy. Additionally, we found that TBK1 inhibits insulin receptor signaling in the HFD setting, a function that is absent in Tbk1 D/D animals. As a result, 
MATERIALS AND METHODS

Animals
Tbk1 D/D mice were generated in a pure 129S5 strain as previously described [17] and were generously provided by Pfizer (Cambridge, 
Immunoprecipitation
Briefly, liver tissue lysates were prepared by lysis in TNET buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris ph 8.0, 1% Triton X) plus protease and phosphatase inhibitor cocktails (Thermo Scientific) and 1 mM PMSF. Liver tissue lysate concentrations were assayed using a bicinchoninic acid assay and then equilibrated with lysis buffer. Lysates were pre-cleared by incubation with 20 mL of Protein A/G agarose beads (Thermo Scientific) for 90 min at 4 C followed by centrifugation. Pre-cleared lysates (250 mg/sample) were then incubated with rabbit anti-TBK1 (Cell Signaling, #3031) or rabbit IgG control (Cell Signaling, #2729) and 30 mL of Protein A/G agarose beads and rotated overnight at 4 C. Immunoprecipitates were washed three times in TNET buffer then heated to 95 C for 5 min in standard SDS sample buffer. Samples were separated by SDS-PAGE followed by western blot analysis.
Histology and immunohistochemistry
Fat pads, livers, and pancreas tissues were excised and either frozen in liquid nitrogen and embedded in optimum cutting temperature compound (OCT, Tissue-Tek; EMS, Hatfield, PA) for frozen sections or fixed with 10% neutral buffered formalin solution overnight and embedded in paraffin for sectioning. Frozen liver sections (10 mm)
were air-dried overnight and then fixed in 10% neutral buffered formalin for 10 min at room temperature. After brief rinsing with water and then 60% isopropanol, frozen liver sections were stained with oil red O for 15 min and counterstained with hematoxylin. Formalin-fixed paraffin embedded fat pads and pancreas tissues were cut into 5 mm sections. Paraffin sections were deparaffinized and rehydrated with xylene and serial dilutions of ethanol followed by H&E stain or antigen retrieval with 0.01 mol/L citric acid buffer (pH 6.0) for immunohistochemistry. Sections for immunohistochemical analysis were blocked with 20% aquablock and incubated with rabbit anti-cd11b/c (Novus Biologicals, NB110-40766) in blocking solution (5% BSA in TBS with 0.05% tween) at 4 C overnight. Horseradish peroxidaseeconjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) was used as a secondary antibody. Negative controls included omission of primary antibody. All slides were visualized with a Nikon Eclipse E600 microscope (Nikon, Melville, NY) and color images were captured using a Nikon Digital Dx1200me camera and ACT-1 software. Images were analyzed using NIS Elements AR 2.3 Software (Nikon).
Statistics
Statistical analyses were performed using GraphPad Prism (GraphPad, La Jolla, CA). Results are expressed as mean AE SEM. All data were analyzed by t-test or ANOVA. Significance was accepted at p < 0.05, with asterisks denoting p-value levels: *, p < 0.05; **, p < 0.01; ***, p < 0.001; and ****, p < 0.0001.
RESULTS
HFD induces TBK1 expression and activity
Prolonged consumption of a HFD results in increased expression of IKKε and TBK1 in murine liver and WAT [14, 15] . To confirm and extend these results, we evaluated IKKε and TBK1 expression in liver and subcutaneous WAT tissue collected from HFD-fed C57BL/6 mice. Consistent with earlier reports, TBK1 mRNA levels increased nearly 6-and 3-fold, respectively, in liver and WAT of HFD-fed animals ( Figure 1A ,B). Surprisingly, IKKε transcript levels were not elevated in either set of tissues post HFD, even though IL-6, which is known to be abundant in obese settings, was increased in liver and WAT, confirming the presence of metabolic inflammation in these HFD-fed animals [19, 20] . In addition to confirming TBK1 induction at the protein level in liver tissues, we also observed an increase in TBK1 activity as seen by higher levels of pTBK1 and downstream TBK1 targets, pIRF3 and pp65 ( Figure 1C ). Interestingly, a previous study [21] reported that TBK1 interacts with insulin receptor b subunit (IRb) in livers of obese rats. Concurrent with elevated TBK1 activity, we also detected a robust increase in IRb-associated TBK1 by co-immunoprecipitation in liver lysates from HFD-fed mice compared to normal chow diet (ND) animals ( Figure 1D ). This heightened association could be indicative of a novel insulin-related function for TBK1.
3.2.
Tbk1 D/D mice are resistant to DIO Upon observing the induction of TBK1 expression, activity and IRb interaction on HFD feeding, we sought to resolve TBK1 contributions to metabolism that are distinct from its homolog, IKKε. We did this by utilizing Tbk1 D/D animals [17] . To examine the outcome of metabolic stress in a Tbk1-deficient setting, we placed Tbk1 D/D and Tbk1 þ/þ mice on HFD for 10 weeks. Weight measurements for each group were collected weekly and compared to age-matched ND-fed Tbk1 D/D and Tbk1 þ/þ mice ( Figure 2A ). By 8 weeks of age (4 weeks in the study), we documented a 25% increase in total body weight in HFD-fed Tbk1 þ/þ mice compared to ND. Similar to HFDfed Ikbke À/À mice and amlexanox-treated mice, Tbk1 D/D mice showed only a modest increase in total body weight on HFD relative to ND-fed mice and overall maintained significantly lighter body weights than HFD-fed Tbk1 þ/þ mice through the end of the study (Figure 2A,B) . To confirm that these differences in body weight and fat mass are not due to Tbk1 D/D mice eating less than Tbk1
mice, we evaluated daily food intake relative to body weight. While no significant difference was observed, Tbk1 D/D mice showed a minor increase in the ratio of HFD intake to body weight, eliminating the possibility of reduced consumption ( Figure 2C ). Additionally, there were no differences in body weight and length between NDfed Tbk1 D/D and Tbk1 þ/þ mice, indicating that the resistance to the DIO phenotype seen with Tbk1 D/D mice is unique to this particular which is akin to the phenotype of previously reported Ikbke À/À mice and amlexanox-treated animals ( Figure 3D ,E).
3.4. Loss of TBK1 kinase enhances insulin sensitivity on HFD Munoz et al. [21] also reported that TBK1 can directly phosphorylate serine 994 (S994) of IRb in livers from obese rats. This particular serine site can be phosphorylated by the serine kinase, protein kinase C (PKC, isoforms b2 and q) and has been implicated as an inhibitory phosphorylation site that blocks insulin receptor tyrosine kinase activity and subsequent downstream signaling [22, 23] . Within metabolically diseased tissues from obese patients, there is a high level of proinflammatory cytokines that can drive activation of stress kinases, including Jun N-terminal kinase (JNK), IKKb and PKC [24, 25] . These kinases are thought to respond to inflammation by constraining the activity of the insulin receptor directly or indirectly through IRSs via inhibitory phosphorylation, ultimately bringing insulin signaling down to baseline [26e28] . Given that TBK1 is a serine/threonine IKK (IkB kinase) family member that is responsive to inflammatory stimuli and is capable of phosphorylating the insulin receptor, we hypothesized that TBK1 negatively regulates insulin signaling through phosphorylation of S994 on IRb.
We examined the phosphorylation status of IRb (S994) in liver tissue from ND-and HFD-fed Tbk1 þ/þ and Tbk1 D/D mice with an antibody specific for pIRb (S994). A specific pIRb (S994) signal was detectable only in livers from Tbk1 þ/þ mice in the HFD-fed group ( Figure 4A ).
Furthermore, co-immunoprecipitation of TBK1 in liver lysates showed TBK1-IRb association after HFD feeding and also revealed a pIRb (S994) band exclusively in HFD Tbk1 þ/þ livers ( Figure 4B ). These results confirm that S994 of IRb is phosphorylated in HFD-fed mouse livers and indicate that TBK1 is likely the upstream kinase responsible. Loss of this inhibitory signal in HFD-fed Tbk1 D/D tissue suggests that insulin signaling is intact in HFD-fed Tbk1 D/D animals. We tested this directly by injecting the mice with insulin (1 unit/kg of body weight) or PBS and collected tissues 15 min later for protein isolation. Liver and subcutaneous WAT protein lysates were probed for downstream insulin signaling proteins and phosphoproteins. AKT2 is considered to be the more insulin-responsive isoform of AKT (Protein kinase B, PKB) [29] . In comparison to livers and WAT from ND mice, insulin-induced AKT2 and downstream GSK3b (Glycogen synthase kinase 3b) activation were appreciably lower in HFD Tbk1 þ/þ tissues ( Figure 4C,D) .
On the other hand, tissues from insulin-treated HFD Tbk1 D/D mice maintained consistent AKT2 activation at a level comparable to ND animals. Therefore, loss of TBK1 kinase activity in the context of a metabolic challenge results in the preservation of insulin sensitivity that is normally dampened as a result of HFD. This difference in insulin sensitivity between Tbk1 þ/þ and Tbk1 D/D mice was confirmed by analysis of total IRS1 protein levels across liver, subcutaneous WAT and skeletal muscle. Persistent inhibitory phosphorylation of IRS1 leads to its degradation and ultimately insulin resistance [27] . In light of the observation that Tbk1 D/D mice are more responsive to insulin, we suspected they would have more IRS1 protein present in metabolic tissues relative to HFD-fed Tbk1 þ/þ mice. In the HFD-fed Tbk1 þ/þ group, there was a consistent loss of detectable IRS1 in all 10 tissues examined. Whereas in HFD fed Tbk1 D/D mice, IRS1 was easily detectable in 7 out of 12 tissues examined ( Figure 4E ). Altogether, these findings are consistent with the differences observed in the OGTTs and help to explain why HFD-fed Tbk1 D/D mice were more glucose tolerant than Tbk1 þ/þ mice.
Tbk1 D/D mice expend more energy through physical activity
If lack of functional TBK1 on HFD generates greater insulin responsiveness and subsequent glucose absorption in Tbk1 mutant mice, these animals are likely more efficient in storing and/or expending that energy. Total energy expenditure is composed of voluntary events, such as physical activity, and involuntary events, such as basal metabolic rate and thermogenesis. Thermogenesis was increased in Ikbke À/À mice and amlexanox-treated mice compared to control mice and was determined to be the primary difference contributing to their improved phenotype. The expression of thermogenic genes Ucp1, Ucp2, Pparg and Ppargc1a were not significantly upregulated in HFDfed Tbk1 D/D WAT and livers relative to Tbk1 þ/þ mice (Supplemental Fig. 2A,B) . However, the thermogenic differences detected in Ikbke À/À mice and amlexanox-treated mice were at week 14 of HFD.
Considering the 10-week duration of our HFD study, it is possible that differences in thermogenesis were not given sufficient time to manifest. We evaluated alternative forms of energy expenditure by monitoring Tbk1 þ/þ and Tbk1 D/D mice in metabolic cages over a 72-hour period. While there were no significant differences between ND-fed groups (Supplemental Fig. 3 ), HFD-fed Tbk1 D/D mice were more active than Tbk1 þ/þ mice as quantified by their increased movement (beam breaks) throughout the cages ( Figure 5A ). Accordingly, Tbk1 D/D mice also had 22% higher oxygen consumption, 25% higher carbon dioxide production and 23% higher heat production, demonstrating greater energy expenditure overall ( Figure 5B ). Of note, the greatest differences in activity and energy expenditure took place during the dark cycles when the animals were awake. Since mice are nocturnal animals, any differences in resting metabolic rate between the two groups would be apparent during the light or daytime hours. Tbk1 D/D mice had only a modest increase in movement and energy expenditure during light cycles, indicating that the enhanced nighttime physical activity observed in Tbk1 D/D mice could account for their increased energy expenditure relative to Tbk1 þ/þ mice.
Alongside beam break and energy expenditure measurements, body composition analysis of Tbk1 þ/þ and Tbk1 D/D mice was performed utilizing a nuclear MRI mini spec instrument. Lean and fat mass composition were similar between ND mice, while HFD-fed Tbk1
animals had 70% more fat mass and 15% less lean mass compared to ND mice ( Figure 5C,D) . In contrast, HFD-fed Tbk1 D/D mice contained fat and lean body masses nearly equivalent to ND-fed mice, possibly due in part to their higher energy expenditure. Overall, these findings are in agreement with the insulin and glucose tolerant state of Tbk1 D/D mice and indicate that they consume more energy via increased activity, accounting for greater lean mass and reduced fat mass.
3.6. HFD-fed Tbk1 D/D mice maintain lipid homeostasis Differences in fat mass and lipid accumulation were also examined. HFD induces adipocyte enlargement and proliferation in WAT. In subcutaneous fat pads collected from HFD-fed Tbk1 þ/þ mice, we observed larger adipocytes compared to those collected from ND-fed Tbk1 þ/þ mice ( Figure 6A ). While we did see larger adipocytes in fat pads from HFD-fed Tbk1 D/D mice, overall, they contained a greater abundance of small adipocytes relative to HFD-fed Tbk1 þ/þ fat tissue ( Figure 6A,B) . Additionally, cholesterol levels were measured from plasma of ND-and HFD-fed Tbk1 þ/þ and Tbk1 D/D mice. As expected, a prolonged fat diet led to a nearly 40% increase in circulating cholesterol in Tbk1 þ/þ mice ( Figure 6C ). Yet, Tbk1 D/D mice maintained cholesterol levels comparable to mice on ND. mice preserve lipid homeostasis and maintain a consistently healthier phenotype.
3.7. Diet-induced inflammation is nominal in Tbk1 D/D mice Chronic low-grade inflammation, also referred to as "meta-inflammation," is a hallmark of metabolic syndrome and strongly associates with insulin resistance. It is characterized by a high degree of immune cell infiltration, primarily macrophages, and local cytokine production in metabolically diseased tissues. Meta-inflammation is thought to stem from pathological adipocyte tissue expansion in an obese state where the tissue becomes poorly oxygenated or hypoxic. Hypoxia leads to fibrosis and necrotic cell death in adipose tissue, which provokes local macrophage activation and/or polarization to an "M1" proinflammatory state. Inflammation is augmented by adipocytes and macrophages that generate proinflammatory cytokines to promote macrophage mobilization from bone marrow and local infiltration into adipose tissue and other metabolically diseased tissues [30] . Figure 7C ). Furthermore, WAT and liver protein lysates were analyzed for differences in cytokine expression by multiplex immunoassays. Cytokine levels showed little variance between ND-fed groups, which is consistent with the relatively mild immune phenotype of Tbk1 D/D animals (Supplemental Fig. 4A ,B) [17] . Among the HFD-fed animals, Tbk1 D/D mice had less cytokine accumulation compared to Tbk1 þ/þ mice and in particular, IL-6, IL-1b and TNFa levels were consistently lower in WAT and liver tissues from Tbk1 D/D mice ( Figure 7D ,E).
DISCUSSION
Numerous studies have demonstrated TBK1 as a key mediator in inflammatory and innate immune responses. However, recent evidence implicating TBK1 in the regulation of insulin receptor activity has emerged, leading us to investigate a novel metabolic function of this serine threonine kinase [21,31e34] . Our data corroborate previously reported upregulation of TBK1 expression on HFD and also show increased pIRF3, indicating heightened TBK1 kinase activity as well. In our DIO model, we confirmed the inhibitory interaction between TBK1 and IRb and demonstrate that insulin sensitivity is maintained under HFD conditions in the absence of functional TBK1, supporting a previously unappreciated function of TBK1 in regulating insulin receptor activity. Tbk1 D/D mice are resistant to DIO, and we suspect that this stems primarily from their enhanced insulin sensitivity, allowing for more efficient glucose uptake and utilization. Accordingly, these mice Original Article exhibited greater energy expenditure primarily in the form of enhanced physical activity, which accounts for their leaner body composition. These results provide a mechanistic basis for the overall protective effect on the metabolism and general health of Tbk1 D/D mice challenged with a HFD. An important consideration with this study is that the Tbk1 D/D mice contain a global mutation in Tbk1, thereby inhibiting its kinase activity and significantly reducing its overall expression in all cell types. Thus, it is unclear if the Tbk1 D/D mouse phenotype is due to Tbk1 loss in a specific subset or subsets of tissues or cell types. Interestingly, conditional deletion of Tbk1 in adipose tissue (Tbk1 ATKO) resulted in higher macrophage and proinflammatory cytokine gene expression on HFD [18] . In contrast to our model, HFD-fed Tbk1 ATKO mice were insulin resistant and glucose intolerant. This information, in conjunction with the restricted inflammatory response produced by lipopolysaccharide (LPS) stimulated macrophages from the Tbk1 D/D mice, leads us to speculate whether myeloid cell loss of TBK1 is critical to maintaining insulin sensitivity under metabolic stress [17, 35] . In a similar vein, myeloid cell specific knockout of Ikbkb (IKKb gene) in HFD fed mice resulted in improved insulin resistance and lower adiposity, supporting the central contribution of myeloid cells in the development of systemic insulin resistance [7] . With our Tbk1 D/D model, we conclude that the observed phenotype is the effect of systemically eliminating TBK1 catalytic activity. From a clinical perspective, global loss of TBK1 kinase function could be biologically analogous in some respects to the effects of small molecule inhibition of TBK1 system wide.
The relationship between inflammation and insulin resistance is complex and somewhat controversial. In particular, modulating the expression of certain inflammatory signaling molecules such as IKKb, JNK, TNFa, IL-1R or IL-6 in different tissues or by different methods has led to inconsistent metabolic outcomes [36] . For example, liver specific JNK activation improved insulin sensitivity, yet activation of JNK in other tissues, including adipose tissue, skeletal muscle and brain, impaired insulin action, suggesting JNK regulation of insulin sensitivity is tissue specific [36e38]. Considering the well-established functions of TBK1 in mediating inflammation and innate immunity, we cannot rule out the possibility that some of the healthier metabolic parameters seen in Tbk1 D/D mice could be due in part to reduced inflammation, especially given that Tbk1 D/D macrophages show only a partial response to LPS challenge [17] . While these results are consistent with the argument that inflammation leads to insulin resistance, the scope of this study limits the use of the inflammatory phenotype to function as an indicator of metabolic health in Tbk1 D/D mice. Regardless, our results strongly suggest that TBK1 promotes metabolic dysfunction through negative regulation of insulin receptor signaling, thus aiding in insulin resistance. This feature of TBK1 is reminiscent of other kinases that have been previously shown to inhibit insulin signaling in response to cytokine activation. In particular, IKKb, JNK, PKC, and S6K have each been shown to phosphorylate IRS proteins at unique sites that limit insulinstimulated activity [26e28]. Accordingly, S6K1-deficient mice demonstrate a comparable phenotype to Tbk1 D/D mice on HFD with lower body weights and insulin hypersensitivity [39, 40] . The opposition of insulin-stimulated anabolic processes common to all of these kinases is indicative of an evolutionary conserved role in reserving energy during times of inflammatory stress for resolving inflammation. In summary, we have characterized the phenotype of mice globally lacking catalytically active TBK1 under metabolic challenge, which, prior to this mouse, was impossible due to embryonic lethality in Tbk1 À/À mice [16, 17] . Overall, loss of TBK1 kinase activity benefited mice challenged with HFD. One way that TBK1 promotes metabolic syndrome progression is by directly impeding insulin receptor signaling, resulting in systemic insulin resistance and limited glucose absorption. While work from others has begun to elucidate the tissue specific effects of TBK1, it is unclear whether additional TBK1 substrates could be mediating these metabolic effects [18] . A recent study from Kumari and colleagues [41] revealed that the TBK1 substrate IRF3 transcriptionally drives adipose inflammation during periods of overnutrition. IRF3 was upregulated and more active in metabolic tissues from obese mice, matching our observations, while Irf3 À/À mice were protected from DIO, exhibited reduced inflammation and showed improved insulin sensitivity on HFD. This finding helps elaborate the function of TBK1 under metabolic stress, but also highlights the need for further investigation of TBK1 targets in regulating metabolism. Lastly, our results, in conjunction with other previous reports, imply that TBK1 inhibition may provide benefits to patients with metabolic syndrome and warrants further testing of pharmacological inhibitors of TBK1 in human trials [14, 15, 18, 42, 43] . The TBK1/IKKε inhibitor amlexanox just completed testing in clinical trials beginning with a safety trial of six patients in which no serious adverse events were reported from drug treatment (NCT01842282) [44] . The safety trial was followed by a randomized, double-blind, placebo-controlled trial of 42 obese patients with type 2 diabetes or nonalcoholic fatty liver disease who received amlexanox or placebo for 12 weeks (NCT01975935). A subset of patients constituting one-third of the participants in the blinded study responded with a clinically significant reduction in blood glucose. Interestingly, molecular analysis of fat tissue biopsies collected from patients at the beginning of the study revealed greater inflammation in the responder group compared to non-responders. Though it is unclear whether this high level of inflammation in the responder group showed any sort of resolution by the end of the study, further development and confirmation of this inflammatory gene signature could lead to its utilization as a predictive tool for patient response to amlexanox or potentially other TBK1 inhibitors. Future studies are needed with larger patient groups to validate the efficacy of amlexanox, determine the appropriate dosage and dosing schedule and evaluate whether amlexanox treatment has long-term benefits.
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